OSE Immunotherapeutics

144 articles with OSE Immunotherapeutics

• Selexis SA And OSE Immunotherapeutics Collaborate To Advance Development Of Immunotherapies For Cancer And Autoimmune Diseases

  11/15/2016

• OSE Immunotherapeutics To Present The Preclinical Data Of Its New Checkpoint Inhibitor Effi-DEM On SIRP-a/CD47 Strategic Pathway At The 2016 Immune Checkpoint Inhibitors Conference

  10/4/2016

• OSE Immunotherapeutics To Present Atalante 1, The Registration Clinical Trial Of Tedopi, Ongoing In The U.S. And In Europe, At The World Conference On Lung Cancer (WCLC)

  9/20/2016

• OSE Immunotherapeutics Forges $173 Million Autoimmune Deal with Johnson & Johnson

  7/6/2016